ProMIS Neurosciences Inc. Common Shares (ON) (PMN)

About ProMIS Neurosciences Inc. Common Shares (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Institutional ownership

In 13F filings for the quarter ended June 30, 2026, 27 institutions reported holding PMN, with 6.4 million shares worth $84.3 million in aggregate. The largest reported holder was Janus Henderson (Jupiter Topco), with 1.3 million shares worth $17.0 million. Of the 5 largest holders listed below, 1 added shares and 4 held their positions unchanged during the quarter.

Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.

Frequently asked questions